These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
485 related articles for article (PubMed ID: 9831867)
1. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Ross JS; Fletcher JA Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867 [TBL] [Abstract][Full Text] [Related]
2. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Ross JS; Fletcher JA Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301 [TBL] [Abstract][Full Text] [Related]
3. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Ross JS; Fletcher JA Semin Cancer Biol; 1999 Apr; 9(2):125-38. PubMed ID: 10202134 [TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Ross JS; Gray GS Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077 [TBL] [Abstract][Full Text] [Related]
5. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Ross JS; Fletcher JA Oncologist; 1998; 3(4):237-252. PubMed ID: 10388110 [TBL] [Abstract][Full Text] [Related]
6. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689 [TBL] [Abstract][Full Text] [Related]
7. Breast cancer in the 21st century: neu opportunities and neu challenges. Schnitt SJ Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529 [TBL] [Abstract][Full Text] [Related]
8. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Hanna WM; Kahn HJ; Pienkowska M; Blondal J; Seth A; Marks A Mod Pathol; 2001 Jul; 14(7):677-85. PubMed ID: 11455000 [TBL] [Abstract][Full Text] [Related]
9. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
12. The role of the HER-2/neu oncogene in gynecologic cancers. Cirisano FD; Karlan BY J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816 [TBL] [Abstract][Full Text] [Related]
13. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Gong Y; Booser DJ; Sneige N Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420 [TBL] [Abstract][Full Text] [Related]
14. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494 [TBL] [Abstract][Full Text] [Related]
15. [Detection of HER-2/neu in breast carcinoma]. Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438 [TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506 [TBL] [Abstract][Full Text] [Related]
18. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Prati R; Apple SK; He J; Gornbein JA; Chang HR Breast J; 2005; 11(6):433-9. PubMed ID: 16297088 [TBL] [Abstract][Full Text] [Related]
19. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574 [TBL] [Abstract][Full Text] [Related]
20. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]